These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16359855)

  • 1. mTOR and cancer: reason for dancing at the crossroads?
    Thomas GV
    Curr Opin Genet Dev; 2006 Feb; 16(1):78-84. PubMed ID: 16359855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy.
    Harding MW
    Clin Cancer Res; 2003 Aug; 9(8):2882-6. PubMed ID: 12912931
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting the mTOR signaling network in cancer.
    Chiang GG; Abraham RT
    Trends Mol Med; 2007 Oct; 13(10):433-42. PubMed ID: 17905659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting mTOR for cancer treatment.
    Rubio-Viqueira B; Hidalgo M
    Curr Opin Investig Drugs; 2006 Jun; 7(6):501-12. PubMed ID: 16784020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting mTOR in renal cell carcinoma.
    Hudes GR
    Cancer; 2009 May; 115(10 Suppl):2313-20. PubMed ID: 19402072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.
    Bertoni E; Salvadori M
    J Nephrol; 2009; 22(4):457-62. PubMed ID: 19662600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of mTOR in the management of solid tumors: an overview.
    Strimpakos AS; Karapanagiotou EM; Saif MW; Syrigos KN
    Cancer Treat Rev; 2009 Apr; 35(2):148-59. PubMed ID: 19013721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma.
    Oudard S; Medioni J; Aylllon J; Barrascourt E; Elaidi RT; Balcaceres J; Scotte F
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):705-17. PubMed ID: 19496707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining the role of mTOR in cancer.
    Guertin DA; Sabatini DM
    Cancer Cell; 2007 Jul; 12(1):9-22. PubMed ID: 17613433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.
    Bjelogrlić SK; Srdić T; Radulović S
    J BUON; 2006; 11(3):267-76. PubMed ID: 17309148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR and cancer therapy.
    Easton JB; Houghton PJ
    Oncogene; 2006 Oct; 25(48):6436-46. PubMed ID: 17041628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The biology behind mTOR inhibition in sarcoma.
    Wan X; Helman LJ
    Oncologist; 2007 Aug; 12(8):1007-18. PubMed ID: 17766661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [mTOR signal pathway and its inhibitors in antitumor therapy: a review].
    Huang JJ; Lin TY
    Ai Zheng; 2007 Dec; 26(12):1397-403. PubMed ID: 18076811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New mTOR inhibitor for renal cell cancer.
    Wilkes GM
    Oncology (Williston Park); 2009 Jul; 23(8 Suppl):54-6. PubMed ID: 19860046
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
    Kapoor A; Figlin RA
    Cancer; 2009 Aug; 115(16):3618-30. PubMed ID: 19479976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
    Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
    Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted cancer therapy: promise and reality.
    Klein S; Levitzki A
    Adv Cancer Res; 2007; 97():295-319. PubMed ID: 17419951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
    Yap TA; Garrett MD; Walton MI; Raynaud F; de Bono JS; Workman P
    Curr Opin Pharmacol; 2008 Aug; 8(4):393-412. PubMed ID: 18721898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis.
    Seeliger H; Guba M; Kleespies A; Jauch KW; Bruns CJ
    Cancer Metastasis Rev; 2007 Dec; 26(3-4):611-21. PubMed ID: 17713840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting mammalian target of rapamycin (mTOR) for health and diseases.
    Tsang CK; Qi H; Liu LF; Zheng XF
    Drug Discov Today; 2007 Feb; 12(3-4):112-24. PubMed ID: 17275731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.